NCT06952010 - A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

November 30, 2027

Conditions

Solid TumorAdvanced Solid TumorMetastatic Solid TumorImmune Sensitive Tumor

Interventions

BIOLOGICAL

XB628

Intravenous infusion(s)

Trial Locations (4)

RECRUITING

Exelixis Clinical Site #1, Hickory

RECRUITING

Exelixis Clinical Site #3, Nashville

RECRUITING

Exelixis Clinical Site #2, San Antonio

RECRUITING

Exelixis Site #4, New Haven